Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) EBIT Margin (2022 - 2023)

Pasithea Therapeutics (KTTA) has disclosed EBIT Margin for 2 consecutive years, with 1100.81% as the latest value for Q2 2023.

  • Quarterly EBIT Margin rose 1812870.0% to 1100.81% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 4832.43% through Mar 2024, down 151181.0% year-over-year, with the annual reading at 2587.35% for FY2022, 2733838.0% up from the prior year.
  • EBIT Margin hit 1100.81% in Q2 2023 for Pasithea Therapeutics, down from 5386.03% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 5386.03% in Q1 2023 to a low of 19229.5% in Q2 2022.